Corporate Social Responsibility

Contents Page

1. Introduction ........................................................................................................2
2. The stance of Pfizer ............................................................................................3 2.1 Theories of corporate social responsibility and ethics ...................................3 2.2 Pfizer 's stance on CSR and ethics ..................................................................4
Bribery of Big Pharma 's ........................................................................................5 3.1 Overseas Commercial bribe ...........................................................................5 3.2 Pfizer in bribery crisis ....................................................................................6
Reaction and negative impacts ..............................................................................7 4.1 Risks of Pfizer ................................................................................................9 4.2 Change the implicit rule .................................................................................9
Conclusion .............................................................................................................10
List of figures ..............................................................................................................12
Bibliography ................................................................................................................13

Introduction
The core of Pfizer 's corporate responsibility is to support sustainable development, then focus on a wide range of development, including innovative solutions to global health issues and contributions, and adhere to the highest ethical standards in the research and development of marketing, in order to adapt to the rapid development of the world (Pfizer annual

Bibliography: Ball,P. 2012. GlaxoSmithKline 's bribes are evidence that Big Pharma isn 't working. [online] Available at: http://www.guardian.co.uk/commentisfree/2012/jul/04/glaxosmithkline-big-pharma-not-working/print [Accessed Oct 26 2012]. BSR20. 2010. Case Studies Pfizer: Focusing, Refining, and Aligning CSR with a New Strategy.[online] Available at: https://www.bsr.org/en/our-insights/case-study-view//pfizer-focusing-refining-and-aligning-csr-with-a-new-strategy [Accessed Oct 25 2012]. Badcott, D. 2012. Big Pharma: a former insider’s view. Medicine, Health Care and Philosophy.[online] DOI: 10.1007/s11019-012-9388-6. Available at: http://www.springerlink.com/content/e071834033466wu6/ [Accessed Oct 24 2012]. Company Spotlight: Pfizer. 2004. MarketWatch: Personal Care, 3(11), pp. 15-21. Cuillla, J.B., 2011. Is Business Ethics Getting Better? A Historical Perspective. Business Ethics Quarterly, 21(2), pp. 335-343. CBC News. 2010. Pfizer to pay $142M for drug fraud. [online] Available at: http://www.cbc.ca/news/health/story/2010/03/25/gabapentin-ubc.html?ref=rss [Accessed Oct 27 2012]. Datamonitor: Pfizer Inc. 2011. Pfizer, Inc.- SWOT Analysis, , pp. 1-9. Elkind, P., Reingold, J. and Burke, D., 2011. Inside Pfizer 's Palace Coup. (cover story). Fortune, 164(3), pp. 76-91. Ericson, J., 2009. Pfizer 's Prescription for Data. (cover story). Information Management (1521-2912), 19(3), pp. 12-17. Evans,R.G. 2010. Tough on Crime? Pfizer and the CIHR. Healthc Policy [online] 2010 May; 5(4): 16–25. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875889/ [Accessed Oct 26 2012]. Esteban, D., 2008. Strengthening corporate social responsibility in the pharmaceutical industry. Journal of Medical Marketing, 8(1), pp. 77-79. Kelton, E. 2012. Forbes. Big Pharma 's Offshore Fraud Strategy. [online] Available at: http://www.forbes.com/sites/erikakelton/2012/09/11/big-pharmas-offshore-fraud-strategy/ [Accessed Oct 26 2012]. Lange, D. and WashBurn, N.T., 2012. Understanding Attributions of Corporate Social Irresponsibility. Academy of Management Review, 37(2), pp. 300-326. Leisinger, K.M., 2005. The Corporate Social Responsibility of the Pharmaceutical Industry: Idealism without Illusion and Realism without Resignation. Business Ethics Quarterly, 15(4), pp. 577-594. Munro, D. 2012. Pharma 's Free Ride in Healthcare Reform. [online] Available at: http://www.forbes.com/sites/danmunro/2012/03/05/pharmas-free-ride-in-healthcare-reform/2/ [Accessed Oct 26 2012]. News Briefs, Pfizer Agrees to Pay $60 Million to Settle Charges Brought Under the Foreign Corrupt Practices Act (Fcpa). 2012. Managing Accounts Payable, 12(9), pp. 15-15. Nussbaum, A.K., 2009. Ethical corporate social responsibility (CSR) and the pharmaceutical industry: A happy couple? Journal of Medical Marketing, 9(1), pp. 67-76. Pfizer. 2012. Responsibility. [online] Available at: http://www.pfizer.com/responsibility/ [Accessed Oct 27 2012]. Pfizer. 2011. Pfizer annual review.[online] Available at: http://www.pfizer.com/investors/financial_reports/annual_reports/2011/index.jsp [Accessed Oct 26 2012]. Palazzolo, J. The Wall Street Journal. 2011. Critics Target Bribery Law. [online] Available at: http://online.wsj.com/article/SB10001424052970204753404577064061604755308.html [Accessed Oct 24 2012]. Pfizer/Johnson & Johnson: discontinuation of IV bapineuzumab places solanezumab under scrutiny. 2012. PharmaWatch: CNS, 11(9), pp. 4-4. Smith,N.C. 2003. Corporate Social Responsibility: Not Whether, But How? Centre for Marketing Working Paper [online] No. 03-701 Available at: http://www.london.edu/facultyandresearch/research/docs/03-701.pdf [Accessed Oct 26 2012]. Silverman, E. 2012. Pfizer To Pay $60M For Making Foreign Bribes. [online] Available at: http://ycharts.com/analysis/story/pfizer_to_pay_60m_for_making_foreign_bribes [Accessed Oct 25 2012]. Stathis, M. 2010. Killing You with Drugs: Legally. [online] Available at: http://www.marketoracle.co.uk/Article18652.html [Accessed Oct 27 2012]. Salzman, A. 2012. Pfizer Slips on Bribery Settlement, Drug Disappointment. [online] Available at: http://blogs.barrons.com/stockstowatchtoday/2012/08/07/pfizer-slips-on-bribery-settlement-drug-disappointment/ [Accessed Oct 25 2012]. Verschoor, C.C., 2012. A Disturbing 30 Days. Strategic Finance, , pp. 11-13. Vasovic, A., Hirschler, B. 2012. Investigations Of Bribery By Big Pharma In Emerging Markets. [online] Available at: http://fairwhistleblower.ca/content/investigations-bribery-big-pharma-emerging-markets [Accessed Oct 27 2012]. Weintraub, A., 2009. Will Pfizer 's Giveaway Drugs Polish its Public Image? BusinessWeek, (4141), pp. 13-13. Weintraub, A., Arndt, M. and Brady, D., 2006. The Lawyer is in at Pfizer. BusinessWeek, (3997), pp. 26-29. Wilson, D. 2010. The New York Times, Business. Pfizer Gives Details on Payments to Doctors. [online] Available at: http://www.nytimes.com/2010/04/01/business/01payments.html?ref=health&_r=1& [Accessed Oct 25 2012]. Warner, J. 2012. Glaxo Fine: What Will Stop Big Pharma Fraud? [online] Available at: http://ideas.time.com/2012/07/06/glaxo-fine-what-will-stop-big-pharma-fraud/ [Accessed Oct 25 2012]. Zavyalova, A., Pfarere, M.D., Reger, R.K. and Shapiro, D.L., 2012. Managing the Message: the Effects of Firm Actions and Industry Spillovers on Media Coverage Following Wrongdoing. Academy of Management Journal, 55(5), pp. 1079-1101.